Seek Returns logo

NVO vs. TMUS: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at NVO and TMUS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

NVO trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, TMUS is a standard domestic listing.

SymbolNVOTMUS
Company NameNovo Nordisk A/ST-Mobile US, Inc.
CountryDenmarkUnited States
GICS SectorHealth CareCommunication Services
GICS IndustryPharmaceuticalsWireless Telecommunication Services
Market Capitalization266.59 billion USD255.00 billion USD
ExchangeNYSENasdaqGS
Listing DateApril 30, 1981April 19, 2007
Security TypeADRCommon Stock

Historical Performance

This chart compares the performance of NVO and TMUS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

NVO vs. TMUS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolNVOTMUS
5-Day Price Return2.50%-1.55%
13-Week Price Return-15.20%-2.47%
26-Week Price Return-20.75%-15.42%
52-Week Price Return67.26%8.76%
Month-to-Date Return9.01%-5.35%
Year-to-Date Return-39.81%2.65%
10-Day Avg. Volume5.77M4.21M
3-Month Avg. Volume6.56M4.34M
3-Month Volatility63.71%21.74%
Beta1.550.46

Profitability

Return on Equity (TTM)

NVO

77.86%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

TMUS

19.69%

Wireless Telecommunication Services Industry

Max
27.45%
Q3
19.26%
Median
13.73%
Q1
9.72%
Min
-1.57%

In the upper quartile for the Wireless Telecommunication Services industry, TMUS’s Return on Equity of 19.69% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

NVO vs. TMUS: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Net Profit Margin (TTM)

NVO

35.61%

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

A Net Profit Margin of 35.61% places NVO in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

TMUS

14.53%

Wireless Telecommunication Services Industry

Max
23.76%
Q3
13.90%
Median
10.68%
Q1
5.59%
Min
-1.18%

A Net Profit Margin of 14.53% places TMUS in the upper quartile for the Wireless Telecommunication Services industry, signifying strong profitability and more effective cost management than most of its peers.

NVO vs. TMUS: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Operating Profit Margin (TTM)

NVO

45.78%

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

An Operating Profit Margin of 45.78% places NVO in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

TMUS

23.08%

Wireless Telecommunication Services Industry

Max
29.85%
Q3
23.51%
Median
20.15%
Q1
16.37%
Min
8.96%

TMUS’s Operating Profit Margin of 23.08% is around the midpoint for the Wireless Telecommunication Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

NVO vs. TMUS: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Profitability at a Glance

SymbolNVOTMUS
Return on Equity (TTM)77.86%19.69%
Return on Assets (TTM)24.22%5.78%
Net Profit Margin (TTM)35.61%14.53%
Operating Profit Margin (TTM)45.78%23.08%
Gross Profit Margin (TTM)83.95%63.61%

Financial Strength

Current Ratio (MRQ)

NVO

0.78

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

TMUS

1.21

Wireless Telecommunication Services Industry

Max
1.26
Q3
0.98
Median
0.71
Q1
0.56
Min
0.37

TMUS’s Current Ratio of 1.21 is in the upper quartile for the Wireless Telecommunication Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

NVO vs. TMUS: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

NVO

0.59

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

TMUS

1.45

Wireless Telecommunication Services Industry

Max
2.80
Q3
2.17
Median
1.52
Q1
0.93
Min
0.48

TMUS’s Debt-to-Equity Ratio of 1.45 is typical for the Wireless Telecommunication Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NVO vs. TMUS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Interest Coverage Ratio (TTM)

NVO

149.07

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.

TMUS

5.31

Wireless Telecommunication Services Industry

Max
12.67
Q3
6.47
Median
3.79
Q1
1.76
Min
-0.02

TMUS’s Interest Coverage Ratio of 5.31 is positioned comfortably within the norm for the Wireless Telecommunication Services industry, indicating a standard and healthy capacity to cover its interest payments.

NVO vs. TMUS: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Financial Strength at a Glance

SymbolNVOTMUS
Current Ratio (MRQ)0.781.21
Quick Ratio (MRQ)0.561.08
Debt-to-Equity Ratio (MRQ)0.591.45
Interest Coverage Ratio (TTM)149.075.31

Growth

Revenue Growth

NVO vs. TMUS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

NVO vs. TMUS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

NVO

3.06%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

NVO’s Dividend Yield of 3.06% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

TMUS

1.48%

Wireless Telecommunication Services Industry

Max
8.69%
Q3
5.44%
Median
3.79%
Q1
2.67%
Min
0.00%

TMUS’s Dividend Yield of 1.48% is in the lower quartile for the Wireless Telecommunication Services industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

NVO vs. TMUS: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Dividend Payout Ratio (TTM)

NVO

61.60%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

TMUS

30.87%

Wireless Telecommunication Services Industry

Max
169.59%
Q3
122.96%
Median
73.67%
Q1
63.98%
Min
1.50%

TMUS’s Dividend Payout Ratio of 30.87% is in the lower quartile for the Wireless Telecommunication Services industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

NVO vs. TMUS: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Dividend at a Glance

SymbolNVOTMUS
Dividend Yield (TTM)3.06%1.48%
Dividend Payout Ratio (TTM)61.60%30.87%

Valuation

Price-to-Earnings Ratio (TTM)

NVO

15.02

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 15.02 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

TMUS

20.82

Wireless Telecommunication Services Industry

Max
31.43
Q3
21.97
Median
16.89
Q1
12.46
Min
7.52

TMUS’s P/E Ratio of 20.82 is within the middle range for the Wireless Telecommunication Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

NVO vs. TMUS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Price-to-Sales Ratio (TTM)

NVO

5.35

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

NVO’s P/S Ratio of 5.35 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

TMUS

3.03

Wireless Telecommunication Services Industry

Max
3.65
Q3
2.21
Median
1.32
Q1
1.17
Min
0.62

TMUS’s P/S Ratio of 3.03 is in the upper echelon for the Wireless Telecommunication Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

NVO vs. TMUS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Price-to-Book Ratio (MRQ)

NVO

8.87

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

TMUS

4.43

Wireless Telecommunication Services Industry

Max
4.87
Q3
2.86
Median
2.07
Q1
1.40
Min
0.40

TMUS’s P/B Ratio of 4.43 is in the upper tier for the Wireless Telecommunication Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

NVO vs. TMUS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Wireless Telecommunication Services industry benchmarks.

Valuation at a Glance

SymbolNVOTMUS
Price-to-Earnings Ratio (TTM)15.0220.82
Price-to-Sales Ratio (TTM)5.353.03
Price-to-Book Ratio (MRQ)8.874.43
Price-to-Free Cash Flow Ratio (TTM)25.3220.61